As J&J Backs Away From The Altar, Guidant Asks Court For Shotgun Wedding
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson is likely to point to Guidant's weak third quarter sales and earnings as evidence that recent recalls have had a "material adverse effect" on Guidant
You may also be interested in...
Boston Scientific Offers $25 Bil. To Nab Guidant From J&J
Convinced that Johnson & Johnson is undervaluing Guidant, Boston Scientific made an offer of $25 bil. for the cardiovascular device firm on Dec. 5 - approximately $3 bil. more than J&J has agreed to pay
Boston Scientific Offers $25 Bil. To Nab Guidant From J&J
Convinced that Johnson & Johnson is undervaluing Guidant, Boston Scientific made an offer of $25 bil. for the cardiovascular device firm on Dec. 5 - approximately $3 bil. more than J&J has agreed to pay
New York State Attorney General Files Suit Against Guidant, Alleging Fraud
New York State Attorney General Eliot Spitzer joined the parade of plaintiffs suing Guidant over issues related to a potentially lethal design flaw in implantable cardioverter defibrillators